Products
Balovaptan is in clinical development and is not yet commercially available. In January 2018, the compound received the FDA’s.
Structure and properties
Balovaptan (C22H24ClN5O, Mr = 409.9 g/mol) structurally belongs to the benzodiazepines.
Effects
Balovaptan improves social interaction and communication in patients with autism. The effects are due to antagonism at vasopressin-1a receptors. Vasopressin is a peptide hormone that plays an important role in the central nervous system during social interactions.
Indications
For the treatment of patients with autism spectrum disorder (ASD/ASD).
